“Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: evaluation of lipid parameters in the phase 3 POETYK PSO-1 and PSO-2 trials” (2023) SKIN The Journal of Cutaneous Medicine, 7(2), p. s115. doi:10.25251/skin.7.supp.115.